|
Real-time Estimate
Cboe BZX
02:02:25 2026-10-20 pm EDT
|
5-day change | 1st Jan Change | ||
| 511.33 USD | +1.87% |
|
+5.03% | +12.41% |
| Oct. 15 | Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653 | MT |
| Oct. 09 | Vertex Pharmaceuticals Says Alyftrek Delivers Pancreatic Function Recovery in Some Children | MT |
Company Valuation: Vertex Pharmaceuticals Incorporated
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 55,834 | 74,127 | 104,849 | 103,707 | 115,026 | 127,225 | - | - |
| Change | - | 32.76% | 41.44% | -1.09% | 10.91% | 10.61% | - | - |
| Enterprise Value (EV) 1 | 48,309 | 63,349 | 93,630 | 97,591 | 108,418 | 120,265 | 117,643 | 114,642 |
| Change | - | 31.13% | 47.8% | 4.23% | 11.09% | 10.93% | -2.18% | -2.55% |
| P/E | 24.4x | 22.5x | 29.3x | -194x | 29.6x | 33.5x | 27x | 22.3x |
| PBR | 5.53x | 5.33x | 5.96x | 6.4x | 6.17x | 8.14x | 6.46x | 5.24x |
| PEG | - | 0.5x | 3.51x | 2x | -0x | -14.51x | 1.1x | 1.1x |
| Capitalization / Revenue | 7.37x | 8.3x | 10.6x | 9.41x | 9.58x | 9.59x | 8.74x | 7.69x |
| EV / Revenue | 6.38x | 7.09x | 9.49x | 8.86x | 9.03x | 9.06x | 8.08x | 6.93x |
| EV / EBITDA | 10.8x | 12.8x | 20.6x | 108x | 19.8x | 27.1x | 18.8x | 16x |
| EV / EBIT | 11.1x | 13.2x | 21.4x | 140x | 20.6x | 21.6x | 19.3x | 15.9x |
| EV / FCF | 20.1x | 16.1x | 28.1x | -123x | 33.9x | 66.7x | 24.8x | 22.2x |
| FCF Yield | 4.99% | 6.2% | 3.56% | -0.81% | 2.95% | 1.5% | 4.03% | 4.51% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 9.01 | 12.82 | 13.89 | -2.08 | 15.32 | 14.97 | 18.6 | 22.53 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 7,574 | 8,931 | 9,869 | 11,020 | 12,001 | 13,268 | 14,565 | 16,542 |
| EBITDA 1 | 4,470 | 4,941 | 4,556 | 902.8 | 5,473 | 4,443 | 6,248 | 7,186 |
| EBIT 1 | 4,344 | 4,793 | 4,375 | 695.6 | 5,263 | 5,576 | 6,108 | 7,221 |
| Net income 1 | 2,342 | 3,322 | 3,620 | -535.6 | 3,953 | 3,884 | 4,887 | 5,862 |
| Net Debt 1 | -7,525 | -10,778 | -11,218 | -6,116 | -6,608 | -6,959 | -9,582 | -12,583 |
| Reference price 2 | 219.60 | 288.78 | 406.89 | 402.70 | 453.36 | 501.95 | 501.95 | 501.95 |
| Nbr of stocks (in thousands) | 254,252 | 256,691 | 257,683 | 257,529 | 253,719 | 253,461 | - | - |
| Announcement Date | 1/26/22 | 2/7/23 | 2/5/24 | 2/10/25 | 2/12/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 33.54x | 9.06x | 27.07x | -.--% | 127B | |
| 35.75x | 12.79x | 26.94x | 0.55% | 1,106B | |
| 37.14x | 6.26x | 17.62x | 2.1% | 612B | |
| 36.08x | 8.31x | 17.14x | 2.43% | 500B | |
| 20.6x | 4.98x | 12.38x | 2.63% | 367B | |
| 104.7x | 5.86x | 25.15x | 2.37% | 354B | |
| 21.05x | 5.51x | 13.55x | 2.9% | 286B | |
| 21.56x | 4.37x | 12.5x | 2.02% | 256B | |
| 26.98x | 6.96x | 12.46x | 2.37% | 230B | |
| -44.72x | 6.87x | 26.59x | 2.15% | 190B | |
| Average | 29.27x | 7.10x | 19.14x | 1.95% | 402.74B | |
| Weighted average by Cap. | 34.38x | 8.14x | 20.11x | 1.79% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- VRTX Stock
- Valuation Vertex Pharmaceuticals Incorporated
Select your edition
All financial news and data tailored to specific country editions
